18
Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Embed Size (px)

Citation preview

Page 1: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence

Jonathan Shuter, M.D.

Treatment Adherence Network Meeting 2/27/01

Page 2: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence--One Extreme

• “I firmly believe that if the whole materia medica as now used could be sunk to the bottom of the sea, it would be all the better for mankind--and all the worse for the fishes.”

1860: Oliver Wendell Holmes to the Massachusetts Medical Society

Page 3: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence--The Other Extreme

D.O.T.

Page 4: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence--The Middle Ground

• Methods that quantify missed and taken doses

• Methods that measure physiologic effects

• Methods that assess systemic blood levels of drug

Page 5: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Self-Report

• Cheap• Correlated with

virologic outcomes (report of non-adherence is more reliable than report of adherence)

• Overestimates adherence

Pro’s Con’s

Page 6: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Clinician-Estimated Adherence

• Cheap • Most poorly correlated of all measures with actual adherence

Pro’s Con’s

PROVIDERS ARE TERRIBLE JUDGES OF ACTUAL ADHERENCE AND OF THEIR PATIENTS’ ABILITY TO ADHERE!

Page 7: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Pill Counts

• Cheap• Useful adjunct to self-

report

• Overestimates adherence– “Pill dumping”

• Time consuming• Casts provider in role

of medication monitor, not ally/advocate

Pro’s Con’s

Page 8: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Pharmacy Records

• Cheap• Useful adjunct to self-

report

• Cannot stand alone as adherence measurement method– One patient may use many

pharmacies

– Picking up prescriptions does not equate with taking medications

– Patients may have other sources of medications

Pro’s Con’s

Page 9: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Electronic Monitoring

• Best correlation with virologic outcomes

• Data is available in a computer accessible format

• Allows more detailed view of non-adherence patterns (weekends, nighttime, etc.)

• Expensive• Poor patient acceptance• Not infallible (patients can

open bottle and not take pill)

• Not compatible with pillbox

• Usually only measures one medication

Pro’s Con’s

Page 10: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence--The Middle Ground

• Methods that quantify missed and taken doses

• Methods that measure physiologic effects

• Methods that assess systemic blood levels of drug

Page 11: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Indirect Laboratory Markers

• AZT=========> Increased MCV

• ddI==========> Increased uric acid

• Indinavir======> Increased bilirubin

Page 12: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Laboratory Markers

• Viral load

• CD4

• Genotypic/phenotypic resistance

Page 13: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Measuring Adherence--The Middle Ground

• Methods that quantify missed and taken doses

• Methods that measure physiologic effects

• Methods that assess systemic blood levels of drug

Page 14: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Plasma Levels

• Correlates with virologic outcomes

• Only method that ensures that the patient actually ingested the drug

• May allow insight into absorption or drug interaction problems

• Very expensive• Levels are extremely

variable• Only provides information

about the last dose

Pro’s Con’s

Page 15: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Montefiore Data

020406080

100120140

Nev

er

Rar

ely

Som

etim

es

Oft

en

Alw

ays

How often do you miss doses of your HIV medications?

Page 16: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Montefiore Data

• 30/106 (28.3%) patients prescribed ART responded “Never” [miss medications], every time they were interviewed.

• These patients are not distinguished by any specific characteristic measured in the study. There are trends toward underrepresentation of females and IDUs in this group.

• Analyzed variables include age, gender, ethnicity, HIV risk behavior, AIDS, adverse effects, and depression score.

Page 17: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

Conclusions

• There is no perfect method or combination of methods available to measure adherence

• Nevertheless, numerous methods of measurement correlate with virologic outcomes, and thus provide useful information

• Some method of adherence measurement should be used for all patients, but decisions regarding which method/s should be individualized

Page 18: Measuring Adherence Jonathan Shuter, M.D. Treatment Adherence Network Meeting 2/27/01

For more HIV-related resources, please visit www.hivguidelines.org